Can Blinatumomab be reimbursed by medical insurance?

Blinatumomab is an attractive biologic agent widely used to treat acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia, ALL). Its unique mechanism and excellent efficacy have attracted widespread attention in the field of leukemia treatment.

Belintuzumab has been launched in China, but it has not been included in medical insurance. Therefore, it cannot be reimbursed by medical insurance. The domestic price is about 10,000 yuan. For specific prices, please consult the local hospital pharmacy.

The mechanism of action of belintuzumab is very unique. It is a type of chimeric T cell receptor (CAR-T) therapy, which strengthens the patient's immune system's attack on leukemia cells by connecting T cells and B cells. Its bispecific antibody structure enables T cells to recognize and destroy CD19-positive B cells, thereby accurately attacking leukemia cells and reducing damage to normal cells.

Belintuzumab has achieved remarkable success in clinical applications. It is often used for refractory or relapsed Bcell acute lymphoblastic leukemia, especially in patients who have become resistant to traditional treatments. Clinical trials have shown that belintuzumab has a significant therapeutic effect and can achieve a complete remission rate of up to 80%. At the same time, its relatively mild side effects can improve the patient's quality of life.

Finally, belintuzumab represents an innovation in the field of leukemia treatment and provides patients with new treatment options. In the future, through continued research and development, we can expect to see its application across a wider range of cancer types and patient populations to improve patient survival and quality of life. The success of this biological agent has also inspired more exploration of how to further improve the effectiveness of leukemia treatment by improving treatment options and reducing side effects.